START: Complete Statistical Analysis of Inhaled Steroid Treatment in Early Asthma

Scope of this record

This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.

1. Trial at a Glance

START was a phase 4 randomized, double-blind, parallel-group treatment trial evaluating inhaled steroid treatment as regular therapy in early asthma.

Feature	START
NCT ID	NCT00641914
Phase	Phase 4
Status	Completed
Enrollment	6800
Condition	Asthma
Sponsor	AstraZeneca
Sponsor type	Industry
Interventions	Budesonide and placebo

2. Clinical Question

Population

Patients with early asthma.

Intervention

Budesonide.

Comparator

Placebo.

Primary question

How does regular inhaled steroid treatment affect severe asthma related events and post-bronchodilator FEV1 % of predicted normal?

3. Trial Design

Design element	Description
Allocation	Randomized
Model	Parallel
Masking	Double
Primary purpose	Treatment
Number of arms	2

4. Endpoints

Endpoint	Time frame
Severe asthma related events (SARE) (part A)	At week 6 and 12, and every 3 months thereafter
Post-bronchodilator FEV1 % of predicted normal (part B)	At week 6 and 12, and every 3 months thereafter

5. Planned Analysis

The ClinicalTrials.gov record lists the primary endpoints but does not report posted statistical analyses or outcome estimates.

For severe asthma related events, a time-to-event or event-rate framework would commonly be considered depending on the prespecified analysis plan, because recurrent clinical events and event timing are important components of asthma outcome assessment.

For post-bronchodilator FEV1 % of predicted normal, analysis would typically focus on comparing lung-function measurements between randomized groups using methods appropriate for continuous outcomes and repeated measurements over time.

Interpretation note: ClinicalTrials.gov does not report formal statistical analyses for the primary endpoints.

6. Statistical Methodology

Randomization

Randomization creates treatment groups that can be compared without assigning patients based on observed or unobserved baseline characteristics. In a double-blind randomized trial, masking helps reduce bias in treatment assignment and outcome assessment.

Repeated measurements

The FEV1 endpoint was assessed repeatedly at week 6, week 12, and every 3 months thereafter. Repeated-measures approaches can account for multiple observations from the same participant while estimating differences between treatment groups over time.

Clinical event analysis

Severe asthma related events represent clinical outcomes rather than laboratory measurements. Statistical approaches for these outcomes generally account for the occurrence and timing of events.

7. Statistical Methods Explained

Why does randomization matter?

Randomization is designed to balance known and unknown prognostic factors between treatment groups, allowing differences in outcomes to be interpreted as treatment comparisons.

Why analyze FEV1 over multiple visits?

Repeated measurements provide information about lung-function patterns over time rather than relying on a single observation.

What is a continuous endpoint?

A continuous endpoint such as FEV1 can take a range of numerical values. Statistical methods compare average patterns or changes between groups.

Why are severe asthma related events different from FEV1?

Events describe clinical occurrences, while FEV1 describes a physiological measurement. They capture different dimensions of asthma control.

Why does blinding matter?

Blinding reduces the possibility that knowledge of treatment assignment influences reporting, assessment, or management decisions.

8. Limitations

The ClinicalTrials.gov record does not report posted statistical analyses or endpoint estimates.
Baseline characteristics, subgroup analyses, and safety results are not reported in the registry information.
The interpretation of treatment effects depends on the prespecified statistical analysis plan and full trial dataset.

9. Why This Trial Matters Statistically

START illustrates several important principles in clinical trial methodology:

Concept	Application
Randomized design	Comparison of budesonide and placebo groups
Double masking	Reduction of assessment bias
Longitudinal measurement	Repeated FEV1 assessments over time
Clinical endpoints	Assessment of severe asthma related events